Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

– Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups –

– In addition to robust liver-centric effects, HU6 resulted in fat-selective weight loss with preservation of skeletal muscle mass; potential to address the metabolic dysfunction underlying MASH –

– HU6 was well tolerated in M-ACCEL, with 450 patients treated to date –

CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating obesity and associated cardiometabolic diseases, today announced the presentation of new clinical data from the Phase 2 M-ACCEL trial evaluating HU6 in patients with MASH (metabolic dysfunction-associated steatohepatitis). These data will be featured in a late-breaker oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 being held November 7-11, 2025, in Washington, DC.

These results build on the positive topline results announced by Rivus in June 2025, showing that the M-ACCEL trial met its primary endpoint, with statistically significant reductions in liver fat content at six months versus placebo (p